New pill aims to tame genital herpes outbreaks
NCT ID NCT06698575
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests an experimental drug called ABI-1179 in healthy volunteers and people with recurrent genital herpes caused by HSV-2. The main goal is to check safety and how the body processes the drug. Researchers will give single or multiple doses and monitor for side effects. This is a first step to see if the drug is safe enough for larger trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ABI-1179 (an experimental antiviral drug taken as a tablet)
- What this could lead to
- If this early study shows the drug is safe and well-tolerated, it could pave the way for a new treatment option to reduce herpes outbreaks.
- What could go wrong
- This is a very early Phase 1 trial focused on safety and dosing, not on whether the drug actually works. Many drugs fail in later stages, so there is no guarantee this will become a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
103 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Part A: Inclusion Criteria: * Subject has a body mass index (BMI) between ≥18.0 and \<32.0 kg/m2 * In good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results. * Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day-1 or Day 1 (predose). * Agreement to comply with protocol-specified contraceptive requirements. Part B: Inclusion Criteria: * Subject has a body mass index (BMI) between ≥18.0 and \<32.0 kg/m2 * Other than HSV infection, is in good health (as determined by the investigator) based on medical history, physical examination, ECG, and clinical laboratory results. * Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 (predose). * Agreement to comply with protocol-specified contraceptive requirements Part A and B: Exclusion Criteria: * Current infection of human immunodeficiency virus (HIV), hepatitis B virus, (HBV), hepatitis C virus (HCV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV). * History of any illness that, in the opinion of the Investigator, might confound the results of the study, pose an additional risk in administering study drug to the subject, or condition known to interfere with the absorption /distribution/ elimination of drugs. * History of any significant drug-related allergic reactions such as anaphylaxis, Stevens-Johnson Syndrome, urticaria, or multiple drug allergies. * History of persistent alcohol abuse or illicit drug abuse within 3 years prior to screening. * Has participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 half-lives before screening, whatever is longer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recurrent genital herpes simplex type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alliance for Multispecialty Research
Kansas City, Missouri, 64114, United States
-
Canopy Clinical Wollongong
Wollongong, Australia, 2500, Australia
-
East Sydney Doctors
Darlinghurst, Australia, 2010, Australia
-
Momentum Clinical Research
Sydney, Australia, 2010, Australia
-
Momentum Kapiti
Waikanae, New Zealand, 5036, New Zealand
-
Momentum Palmerston North
Palmerston North, New Zealand, 4414, New Zealand
-
Momentum Sunshine
Melbourne, Au, 3021, Australia
-
New Zealand Clinical Research
Auckland, New Zealand, 1010, New Zealand
-
New Zealand Clinical Research
Christchurch, New Zealand, 8011, New Zealand
-
Pacific Clinical Research Network
Nelson, New Zealand, 7011, New Zealand
-
Pacific Clinical Research Network
Rotorua, New Zealand, 3010, New Zealand
-
Pacific Clinical Research Network
Upper Hutt, New Zealand, 5018, New Zealand
-
Pacific Clinical Research Network
Hamilton, New, 3200, New Zealand
-
Rochester Clinical Research
Rochester, New York, 14609, United States
-
Royal Melbourne Hospital
Parkville, Australia, 3050, Australia
-
Seattle Clinical Research Center
Seattle, Washington, 98104, United States
-
Taylor Square Private Clinic
Surry Hills, Australia, 2010, Australia
-
University of Washington Virology Research Clinic
Seattle, Washington, 98104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.